There is currently no specific evidence regarding the pathogenesis of MRONJ and no definitively accepted treatment. Inhibition of bone remodeling is thought to lead to reduced mechanical damage and the resulting accumulation of areas of bone necrosis. When used in therapeutic doses, bisphosphonates inhibit the resorptive activity of osteoclasts, while stimulating the differentiation and bone deposition of osteoblasts. As a result, the bone regeneration mechanism is impaired and the risk of avascular necrosis increases as a result of decreased bone remodeling. Bone resorption markers type I Collagen (Ctx) C-Terminal Telopeptide, Type I Collagen (NTX) N-Telopeptide, Tetrate Resistance Acid Phosphatase Isoform 5b (TRACP 5b), Nuclear Receptor Activator (RANKL) / Osteoprotegerin (OPG), Total Alkaline Phosphatase It has been reported that BRONJ is diagnosed by examining (Talp), Bone Specific Alkaline Phosphatase, Bone Sialoprotein, Pyridnoline, Deoxypyridnoline, Hydroxyproline values. CT is considered a standard method in the evaluation of MRONJ. Treatment of medication-induced osteonecrosis of the jaw basically aims to relieve pain, control secondary infection in soft and hard tissues, and minimize the progression of bone necrosis. Alternative treatment methods for MRONJ such as parathormone, platelet-rich plasma, laser applications, ozone treatment, use of bone morphogenic proteins, pentoxifylline, and surgical debridement guided by fluorescent staining method are also mentioned. The drugs that may be alternatıve to bıphosphonates are Denosumab, Strontıum Ranelate (Sr), Teriparatide, Edta, Stromal Vascular Fractıon Cells (Svf) but further studies are needed to be accepted as a definitive protocol. Despite the complications of bisphosphonate group drugs, their use is widespread and increasing due to their numerous indications. Informing dentists about the mechanism of bisphosphonate-derived drugs, denosumab and anti-angiogenic drugs the treatment of MRONJ and alternative drugs to these group drugs are important for the management of complications that develop due to these drugs.
MRONJ’ın patogenezine dair kesin kanıtlar bulunmamaktadır ve genel kabul görmüş bir tedavi yöntemi mevcut değildir. Kemik remodelasyonunun baskılanması, mekanik hasarın azalmasına ve nekrotik kemik alanlarının birikmesine neden olur. Terapötik dozlarda kullanılan bifosfonat türevi ilaçlar, osteoklastların rezorptif aktivitesini inhibe ederken osteoblastların farklılaşmasını ve kemik yapımını da etkiler. Bu durum, kemik yenilenmesini bozar ve azalan kemik remodelizasyonu nedeniyle avasküler nekroz riskini artırır. MRONJ tanısında; Tip I Kollajen C-terminal Telopeptid (CTX), N-terminal Telopeptid (NTX), TRACP 5b, RANKL/OPG oranı, Total Alkalen Fosfataz (TALP), Kemik Spesifik Alkalen Fosfataz, Kemik Sialoproteini, Piridinolini, Deoksipiridinolini ve Hidroksiprolin gibi kemik yıkım belirteçleri değerlendirilmektedir. Bilgisayarlı tomografi (BT), MRONJ’nin değerlendirilmesinde standart yöntemlerden biridir. Tedavi ise ağrının giderilmesi, yumuşak ve sert dokulardaki sekonder enfeksiyonun kontrolü ve nekrozun ilerlemesinin önlenmesini hedeflemektedir. Parathormon, PRP, lazer, ozon tedavisi, kemik morfogenetik proteinler, pentoksifilin ve floresan boyama rehberliğinde cerrahi debridman gibi alternatif tedavi yöntemleri araştırılmaktadır. Bifosfonatlara alternatif olabilecek ilaçlar arasında denosumab, stronsiyum ranelat, teriparatid, EDTA ve stromal vasküler fraksiyon hücreleri (SVF) yeralmaktadır. Ancak bunların kesin protokol haline gelmesi için daha fazla çalışmaya ihtiyaç vardır. Diş hekimlerinin bu ilaçların etkileri ve olası komplikasyonları konusunda bilgilendirilmesi önemlidir.
Primary Language | English |
---|---|
Subjects | Oral and Maxillofacial Surgery, Oral and Maxillofacial Radiology, Oral Medicine and Pathology |
Journal Section | Review |
Authors | |
Publication Date | June 30, 2025 |
Submission Date | January 4, 2025 |
Acceptance Date | January 15, 2025 |
Published in Issue | Year 2025Volume: 28 Issue: 2 |
Cumhuriyet Dental Journal (Cumhuriyet Dent J, CDJ) is the official publication of Cumhuriyet University Faculty of Dentistry. CDJ is an international journal dedicated to the latest advancement of dentistry. The aim of this journal is to provide a platform for scientists and academicians all over the world to promote, share, and discuss various new issues and developments in different areas of dentistry. First issue of the Journal of Cumhuriyet University Faculty of Dentistry was published in 1998. In 2010, journal's name was changed as Cumhuriyet Dental Journal. Journal’s publication language is English.
CDJ accepts articles in English. Submitting a paper to CDJ is free of charges. In addition, CDJ has not have article processing charges.
Frequency: Four times a year (March, June, September, and December)
IMPORTANT NOTICE
All users of Cumhuriyet Dental Journal should visit to their user's home page through the "https://dergipark.org.tr/tr/user" " or "https://dergipark.org.tr/en/user" links to update their incomplete information shown in blue or yellow warnings and update their e-mail addresses and information to the DergiPark system. Otherwise, the e-mails from the journal will not be seen or fall into the SPAM folder. Please fill in all missing part in the relevant field.
Please visit journal's AUTHOR GUIDELINE to see revised policy and submission rules to be held since 2020.